Literature DB >> 12645999

Comparison of stepwise covariate model building strategies in population pharmacokinetic-pharmacodynamic analysis.

Ulrika Wählby1, E Niclas Jonsson, Mats O Karlsson.   

Abstract

The aim of this study was to compare 2 stepwise covariate model-building strategies, frequently used in the analysis of pharmacokinetic-pharmacodynamic (PK-PD) data using nonlinear mixed-effects models, with respect to included covariates and predictive performance. In addition, the effects of stepwise regression on the estimated covariate coefficients were assessed. Using simulated and real PK data, covariate models were built applying (1) stepwise generalized additive models (GAM) for identifying potential covariates, followed by backward elimination in the computer program NONMEM, and (2) stepwise forward inclusion and backward elimination in NONMEM. Different versions of these procedures were tried (eg, treating different study occasions as separate individuals in the GAM, or fixing a part of the parameters when the NONMEM procedure was used). The final covariate models were compared, including their ability to predict a separate data set or their performance in cross-validation. The bias in the estimated coefficients (selection bias) was assessed. The model-building procedures performed similarly in the data sets explored. No major differences in the resulting covariate models were seen, and the predictive performances overlapped. Therefore, the choice of model-building procedure in these examples could be based on other aspects such as analyst- and computer-time efficiency. There was a tendency to selection bias in the estimates, although this was small relative to the overall variability in the estimates. The predictive performances of the stepwise models were also reasonably good. Thus, selection bias seems to be a minor problem in this typical PK covariate analysis.

Mesh:

Year:  2002        PMID: 12645999      PMCID: PMC2751316          DOI: 10.1208/ps040427

Source DB:  PubMed          Journal:  AAPS PharmSci        ISSN: 1522-1059


  23 in total

1.  Stepwise selection in small data sets: a simulation study of bias in logistic regression analysis.

Authors:  E W Steyerberg; M J Eijkemans; J D Habbema
Journal:  J Clin Epidemiol       Date:  1999-10       Impact factor: 6.437

2.  Prognostic modelling with logistic regression analysis: a comparison of selection and estimation methods in small data sets.

Authors:  E W Steyerberg; M J Eijkemans; F E Harrell; J D Habbema
Journal:  Stat Med       Date:  2000-04-30       Impact factor: 2.373

3.  Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM.

Authors:  E N Jonsson; M O Karlsson
Journal:  Comput Methods Programs Biomed       Date:  1999-01       Impact factor: 5.428

4.  Lack of an effect of valproate concentration on lamotrigine pharmacokinetics in developmentally disabled patients with epilepsy.

Authors:  B E Gidal; G D Anderson; P R Rutecki; R Shaw; A Lanning
Journal:  Epilepsy Res       Date:  2000-11       Impact factor: 3.045

5.  Automated covariate model building within NONMEM.

Authors:  E N Jonsson; M O Karlsson
Journal:  Pharm Res       Date:  1998-09       Impact factor: 4.200

6.  Population pharmacokinetic model for topotecan derived from phase I clinical trials.

Authors:  J M Gallo; P B Laub; E K Rowinsky; L B Grochow; S D Baker
Journal:  J Clin Oncol       Date:  2000-06       Impact factor: 44.544

7.  Pharmacokinetics of levamisole in cancer patients treated with 5-fluorouracil.

Authors:  P Gwilt; M Tempero; A Kremer; M Connolly; C Ding
Journal:  Cancer Chemother Pharmacol       Date:  2000       Impact factor: 3.333

8.  Pharmacokinetic-Pharmacodynamic Modelling of the antipyretic effect of two oral formulations of ibuprofen.

Authors:  I F Trocóniz; S Armenteros; M V Planelles; J Benítez; R Calvo; R Domínguez
Journal:  Clin Pharmacokinet       Date:  2000-06       Impact factor: 6.447

9.  The pharmacokinetics of theophylline in premature neonates during the first few days after birth.

Authors:  M J du Preez; J H Botha; M L McFadyen; N H Holford
Journal:  Ther Drug Monit       Date:  1999-12       Impact factor: 3.681

10.  Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. The National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators.

Authors:  X J Zhou; L B Sheiner; R T D'Aquila; M D Hughes; M S Hirsch; M A Fischl; V A Johnson; M Myers; J P Sommadossi
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

View more
  81 in total

1.  Power, selection bias and predictive performance of the Population Pharmacokinetic Covariate Model.

Authors:  Jakob Ribbing; E Niclas Jonsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2004-04       Impact factor: 2.745

2.  Disease progression model in subjects with mild cognitive impairment from the Alzheimer's disease neuroimaging initiative: CSF biomarkers predict population subtypes.

Authors:  Mahesh N Samtani; Nandini Raghavan; Yingqi Shi; Gerald Novak; Michael Farnum; Victor Lobanov; Tim Schultz; Eric Yang; Allitia DiBernardo; Vaibhav A Narayan
Journal:  Br J Clin Pharmacol       Date:  2013-01       Impact factor: 4.335

Review 3.  Covariate pharmacokinetic model building in oncology and its potential clinical relevance.

Authors:  Markus Joerger
Journal:  AAPS J       Date:  2012-01-25       Impact factor: 4.009

Review 4.  Recommended reading in population pharmacokinetic pharmacodynamics.

Authors:  Peter L Bonate
Journal:  AAPS J       Date:  2005-10-05       Impact factor: 4.009

5.  Model-based drug development: the road to quantitative pharmacology.

Authors:  Liping Zhang; Vikram Sinha; S Thomas Forgue; Sophie Callies; Lan Ni; Richard Peck; Sandra R B Allerheiligen
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-06-13       Impact factor: 2.745

6.  A genetic algorithm-based, hybrid machine learning approach to model selection.

Authors:  Robert R Bies; Matthew F Muldoon; Bruce G Pollock; Steven Manuck; Gwenn Smith; Mark E Sale
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-03-28       Impact factor: 2.745

7.  Population pharmacokinetics of darbepoetin alfa in healthy subjects.

Authors:  Balaji Agoram; Liviawati Sutjandra; John T Sullivan
Journal:  Br J Clin Pharmacol       Date:  2006-08-30       Impact factor: 4.335

8.  Population pharmacokinetic model and Bayesian estimator for two tacrolimus formulations--twice daily Prograf and once daily Advagraf.

Authors:  Jean-Baptiste Woillard; Brenda C M de Winter; Nassim Kamar; Pierre Marquet; Lionel Rostaing; Annick Rousseau
Journal:  Br J Clin Pharmacol       Date:  2011-03       Impact factor: 4.335

9.  Population Pharmacokinetics of Piperacillin following Continuous Infusion in Critically Ill Patients and Impact of Renal Function on Target Attainment.

Authors:  Vibeke Klastrup; Anders Thorsted; Merete Storgaard; Steffen Christensen; Lena E Friberg; Kristina Öbrink-Hansen
Journal:  Antimicrob Agents Chemother       Date:  2020-06-23       Impact factor: 5.191

Review 10.  What is the best size descriptor to use for pharmacokinetic studies in the obese?

Authors:  Bruce Green; Stephen B Duffull
Journal:  Br J Clin Pharmacol       Date:  2004-08       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.